



Merck's Zepatier Cures Hep C at High Rates in Real-World Analysis

Zepatier (grazoprevir/elbasvir) is approved to treat those with genotypes 1 and 4 of hepatitis C virus.

April 30, 2018

In a recent real-world analysis of Merck's Zepatier (grazoprevir/elbasvir), the regimen cured hepatitis C virus (HCV) at high rates.

Publishing their findings in *Alimentary Pharmacology & Therapeutics*, researchers conducted a retrospective cohort study of adults treated with Zepatier with or without ribavirin who had genotypes 1 or 4 of hep C. Researchers collected data from health care providers and specialty pharmacies through a cloud-based disease management program from Trio Health.

Out of 470 individuals who were treated with Zepatier in 2016, 95 percent had genotype 1 of hep C, 80 percent were being treated for the first time and 70 percent did not have cirrhosis. Eighty-nine percent received 12 weeks of treatment.

Among the 424 people who finished treatment, 99 percent (396 of 402) of those with genotype 1 and 95 percent (21 of 22) of those with genotype 4 achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). Among the 114 people with Stage 4 or 5 chronic kidney disease, 113 (99 percent) were cured.

To read the study, [click here](#).

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.hepmag.com/article/mercks-zepatier-cures-hep-c-high-rates-realworld-analysis>